DS
CAPR icon

David Shaw’s Capricor Therapeutics CAPR Stock Holding History

David Shaw’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98M Buy
+123,746
New +$3.75M ﹤0.01% 2853
2025
Q4 		– Sell
-15,945
Closed -$208K – 4622
2025
Q3 		$115K Buy
15,945
+5,212
+49% +$38.4K ﹤0.01% 4339
2025
Q2 		$107K Buy
+10,733
New +$113K ﹤0.01% 4125
2025
Q1 		– Sell
-53,734
Closed -$742K – 4290
2024
Q4 		$742K Buy
+53,734
New +$942K ﹤0.01% 3386

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's CAPR Position: Q2 2026 in Review

David Shaw opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 123,746 shares worth $2.98M. The stake represents ﹤0.01% of the portfolio and ranks #2853 among its holdings. This is a return to the name: David Shaw previously reported a position in CAPR as recently as Q3 2025.

David Shaw first reported a position in CAPR in Q4 2024 and has held it in 4 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • David Shaw held 123,746 shares of Capricor Therapeutics worth $2.98M as of Q2 2026.
  • Capricor Therapeutics was a new David Shaw position in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2853 holding.
  • David Shaw first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.